Large cell carcinoma of the lung overview: Difference between revisions

Jump to navigation Jump to search
Line 81: Line 81:
===Other Diagnostic Studies===
===Other Diagnostic Studies===


 
Other diagnostic studies for large cell carcinoma of the lung, may include: transthoracic percutaneous [[fine needle aspiration]], [[thoracotomy]], and [[mediastinoscopy]].<ref name="pmid24484269">{{cite journal |vauthors=Kinsey CM, Arenberg DA |title=Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging |journal=Am. J. Respir. Crit. Care Med. |volume=189 |issue=6 |pages=640–9 |year=2014 |pmid=24484269 |doi=10.1164/rccm.201311-2007CI |url=}}</ref>


===Biopsy===
===Biopsy===

Revision as of 16:28, 9 March 2016

Large Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Large Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Large cell carcinoma of the lung overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Large cell carcinoma of the lung overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Large cell carcinoma of the lung overview

CDC on Large cell carcinoma of the lung overview

Large cell carcinoma of the lung overview in the news

Blogs on Large cell carcinoma of the lung overview

Directions to Hospitals Treating Large cell carcinoma of the lung

Risk calculators and risk factors for Large cell carcinoma of the lung overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

Large cell carcinoma of the lung (LCC) is a type of non-small cell carcinoma of the lung, that accounts for 5% and 10% of all lung cancers. Large cell carcinoma of the lung has a moderate causal association with smoking. According to the World Health Organization (WHO), large cell carcinoma of the lung can be classified into 6 sub-types: giant-cell carcinoma of the lung, basaloid large cell carcinoma of the lung, clear cell carcinoma of the lung, lymphoepithelioma-like carcinoma of the lung, large-cell lung carcinoma with rhabdoid phenotype, and large cell neuroendocrine carcinoma of the lung. Large cell carcinoma of the lung arises from the epithelial cells of the lung, which are usually involved in the lining of the airways. The pathological irritation causes the mucus-secreting ciliated pseudostratified columnar respiratory epithelial cells to be replaced by stratified squamous epithelium. Large cell carcinoma of the lung has a peripheral location, and usually appears as a well-circumcised mass attached to the thoracic wall. Large cell carcinoma of the lung is a rapidly growing cancer and frequently has early metastasis. The histologic subtype of large cell neuroendocrine tumor is related with a more aggressive presentation. Genes involved in the pathogenesis of large cell carcinoma of the lung include: EGFR, EML-4, KRAS, HER2, and ALK. On gross pathology, large cell carcinoma of the lung is characterized by well-defined borders, spherical morphology, homogeneous gray-white surface, and bulging appearance. On microscopic pathology, hallmark features of large cell carcinoma of the lung, include: larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin. On immunohistochemistry characteristic features, include: loss of staining with CK5/6, and positive immunoreactivity to EGFR, PDGFR-alpha, and c-kit.

Historical Perspective

In 1976,"The Nurses Health Study" was the first epidemiological study to assess the risk of large cell lung carcinoma with a previous history of tobacco smoking

Classification

According to the World Health Organization (WHO), large cell carcinoma of the lung can be classified into 6 sub-types: giant-cell carcinoma of the lung, basaloid large cell carcinoma of the lung, clear cell carcinoma of the lung, lymphoepithelioma-like carcinoma of the lung, large-cell lung carcinoma with rhabdoid phenotype, and large cell neuroendocrine carcinoma of the lung.

Pathophysiology

Large cell carcinoma of the lung arises from the epithelial cells of the lung, which are usually involved in the lining of the airways. The pathological irritation causes the mucus-secreting ciliated pseudostratified columnar respiratory epithelial cells to be replaced by stratified squamous epithelium. Large cell carcinoma of the lung has a peripheral location, and usually appears as a well-circumcised mass attached to the thoracic wall. Large cell carcinoma of the lung is a rapidly growing cancer. The histologic subtype of large cell neuroendocrine tumor is related with a more aggressive presentation. Genes involved in the pathogenesis of large cell carcinoma of the lung, include: EGFR, EML-4, KRAS, HER2, and ALK. On gross pathology, large cell carcinoma of the lung is characterized by well-defined borders, spherical morphology, homogeneous gray-white surface, and bulging appearance. On micropathology, large cell carcinoma of the lung is characterized by the larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin. On immunohistochemistry characteristic features, include: loss of staining with CK5/6, and positive immunoreactivity to EGFR, PDGFR-alpha, and c-kit.

Causes

In general, causes of large cell carcinoma of the lung are those of non-small cell lung cancers. Common causes include precursor lesions, such as metaplasia or dysplasia induced by smoking, asbestos exposure, ionizing radiation, atmospheric pollution, and chronic interstitial pneumonitis. Less common causes of large cell carcinoma of the lung include chromium and nickel exposure, vinyl chloride exposure, and inorganic arsenic exposure.[1]

Differentiating Large Cell Carcinoma of the Lung from other Diseases

Large cell carcinoma of the lung must be differentiated from other diseases that cause non-productive cough, weight loss, fatigue, and dyspnea among adults such as tuberculosis, pulmonary fungal disease, lung abscess, and more importantly from other causes of non-small cell lung cancers, such as adenocarcinoma and squamous cell lung cancer.[2][3]

Epidemiology and Demographics

Large cell lung cancer accounts for 5% and 10% of all lung cancers. Other subtypes of large cell carcinoma of the lung, such as large cell neureoendocrine carcinoma and lymphoepithelioma-like carcinoma are rare, and represent only 1-3% of lung cancers. Large cell carcinoma of the lung accounts for less than 2% of all cancer deaths. The incidence of large cell carcinoma of the lung increases with age; the median age at diagnosis is approximately 60 years.[4] Large cell carcinoma of the lung is most frequently diagnosed among people among 55 to 65 years old. Males are more commonly affected with large cell carcinoma of the lung than females. Asian race has a higher incidence of lymphoepithelioma-like large lung cell carcinoma compared to the white race.

Risk Factors

The most important risk factor in the development of large cell carcinoma of the lung is cigarette smoking. Other common risk factors in the development of large cell carcinoma of the lung are family history of lung cancer, high levels of air pollution, radiation therapy to the chest, radon gas, asbestos, occupational exposure to chemical carcinogens, and previous history of lung disease.[5]

Screening

According to the U.S. Preventive Services Task Force (USPSTF), screening for large cell carcinoma of the lung by low-dose computed tomography is recommended every year among smokers who are between 55 to 80 years old and who have history of smoke 30 pack-years or more and either continue to smoke or have quit within the past 15 years (grade B recommendation).[6][7][8]

Natural History, Complications and Prognosis

If left untreated, large cell carcinoma of the lung progression occurs rapidly and is then followed by local invasion to chest wall and adjacent lymph nodes.[9] Large cell carcinoma of the lung is a locally aggressive tumor. Large cell carcinoma of the lung is a diagnosis of "exclusion", usually the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. Large cell carcinoma of the lung commonly occurs in adult patients between 55 to 60 years. Common sites of metastasis include adrenal gland, bone, brain, and liver. Complications of large cell carcinoma of the lung, include: acute respiratory failure, malignant pleural effusion, metastases, and pneumonia. Features associated with worse prognosis are presence of lymphatic invasion, location of lesion, gene expression profile, performance status, presence of satellite lesions, and presence of regional or distant metastases. Prognosis is generally regarded as poor.

Diagnosis

Staging

Staging system classification for large cell carcinoma of the lung is same as the non-small cell lung cancer staging. The two main staging systems, include: American Joint Committee on Cancer (AJCC) staging system and International Union Against Cancer (UICC) staging system. According to both institutions, TNM system, which they now develop jointly, classifies cancer by several factors, T for tumor, N for nodes, M for metastasis, and then groups these TNM factors into overall stages.[10] There are 4 stages of large cell carcinoma of the lung: stage I, stage II, stage III, and stage IV [10] Each stage is assigned a letter and a number that designate T for tumor size, N for node invasion, and M for metastasis.

History and Symptoms

The hallmark of large cell carcinoma of the lung is non-productive chronic cough, weight loss, and fatigue. A positive history of smoking, exposure to asbestos, or a high risk occupation may be suggestive of large cell carcinoma of the lung. Symptoms related with large cell carcinoma of the lung will vary depending on the size and location of the tumor. Common symptoms of large cell carcinoma of the lung may also include: shortness of breath, fatigue, and chest pain.[11][12]

Physical Examination

Physical examination findings of large cell carcinoma of the lung will depend on the stage and size of the tumor. Large cell carcinoma of the lung with peripheral location may cause reduced chest expansion, tachypnea, and crackling sounds. Other common physical examination findings of patients with large cell carcinoma of the lung, may include: bubbling noises, decreased/absent breath sounds, and whispered pectoriloquy.[13]

Laboratory Findings

Laboratory findings associated with large cell carcinoma of the lung, include: elevation of LDH or serum tumor markers. Routine laboratory studies for large cell carcinoma of the lung, include: complete blood count, electrolytes, calcium, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, creatinine, albumin, and lactate dehydrogenase.[14][15]

Chest X Ray

On conventional radiography, characteristic findings of large cell carcinoma of the lung, include: large rounded peripheral mass, bulky hilum (representing the tumor and local nodal involvement), and lobar collapse.[16]

CT

Computed tomography is the method of choice for the diagnosis of large cell carcinoma of the lung. On conventional radiography, characteristic findings of large cell carcinoma of the lung, include: large peripheral mass of solid attenuation, irregular margin, and in some cases focal necrosis.[16]

MRI

There are no MRI findings associated with large cell carcinoma of the lung. MRI features helpful in the diagnosis of non-small cell lung cancers, include: pleural effusion assessment, guidance for thoracentesis, guidance for biopsy of peripheral lung or mediastinal mass.[17]

Ultrasound

On endobronchial and endoscopic ultrasound, findings of large cell carcinoma of the lung, may include: enlarged lymph nodes and local invasion to adjacent bronchial structures and mediastinum. Endobronchial ultrasound may be helpful for mediastinal staging of large cell carcinoma of the lung.[18]

Other Imaging Findings

Other imaging findings of large cell carcinoma of the lung, may include: PET/CT and pulmonary angiography.[19]

Other Diagnostic Studies

Other diagnostic studies for large cell carcinoma of the lung, may include: transthoracic percutaneous fine needle aspiration, thoracotomy, and mediastinoscopy.[18]

Biopsy

Biopsy findings associated with large cell carcinoma of the lung, include: larger size of the anaplastic cells, higher cytoplasmic-to-nuclear size ratio, and lack of "salt-and-pepper" chromatin.

Treatment

Medical Therapy

Chemotherapy

Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

References

  1. National Cancer Institute: PDQ® Non-Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified January 22. http://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq. Accessed February 23, 2015
  2. Bhatt M, Kant S, Bhaskar R (2012). "Pulmonary tuberculosis as differential diagnosis of non-small cell lung cancer". South Asian J Cancer. 1 (1): 36–42. doi:10.4103/2278-330X.96507. PMC 3876596. PMID 24455507.
  3. Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R (2009). "A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis". Asian Pac. J. Cancer Prev. 10 (3): 335–8. PMID 19640168.
  4. Meza R, Meernik C, Jeon J, Cote ML (2015). "Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010". PLoS ONE. 10 (3): e0121323. doi:10.1371/journal.pone.0121323. PMC 4379166. PMID 25822850.
  5. Lung cancer. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/lung/risks/?region=ab#Outdoor_air_pollution Accessed February 3, 2016
  6. Lung Cancer: Screening http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening. Accessed on February 3, 2016
  7. Davis AM, Cifu AS. Lung Cancer Screening. JAMA. 2014;312(12):1248-1249. doi:10.1001/jama.2014.12272.
  8. National Lung Screening Trial. Wikipedia. https://en.wikipedia.org/wiki/National_Lung_Screening_Trial Accessed on February 4,2016
  9. Soares M, Darmon M, Salluh JI, Ferreira CG, Thiéry G, Schlemmer B, Spector N, Azoulay E (2007). "Prognosis of lung cancer patients with life-threatening complications". Chest. 131 (3): 840–6. doi:10.1378/chest.06-2244. PMID 17356101.
  10. 10.0 10.1 Stages of non–small cell lung cancer. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/lung/staging/?region=ab
  11. Large cell carcinoma of the lung. Wikipedia. https://en.wikipedia.org/wiki/Non-small-cell_lung_carcinoma Accessed on February 24, 2016
  12. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM (2007). "Natural history of stage I large cell carcinoma of the lung: implications for early detection". Chest. 132 (1): 193–9. doi:10.1378/chest.06-3096. PMID 17505036.
  13. Hyde L, Hyde CI (1974). "Clinical manifestations of lung cancer". Chest. 65 (3): 299–306. PMID 4813837.
  14. Spira A, Ettinger DS (2004). "Multidisciplinary management of lung cancer". N. Engl. J. Med. 350 (4): 379–92. doi:10.1056/NEJMra035536. PMID 14736930.
  15. Shi GL, Hu XL, Yue SD, Song CX (2005). "[The value of serum tumor marker in the diagnosis of lung cancer]". Zhonghua Zhong Liu Za Zhi (in Chinese). 27 (5): 299–301. PMID 15996327.
  16. 16.0 16.1 Rosado-de-Christenson ML, Templeton PA, Moran CA (1994). "Bronchogenic carcinoma: radiologic-pathologic correlation". Radiographics. 14 (2): 429–46, quiz 447–8. doi:10.1148/radiographics.14.2.8190965. PMID 8190965.
  17. Wang YX, Lo GG, Yuan J, Larson PE, Zhang X (2014). "Magnetic resonance imaging for lung cancer screen". J Thorac Dis. 6 (9): 1340–8. doi:10.3978/j.issn.2072-1439.2014.08.43. PMC 4178109. PMID 25276380.
  18. 18.0 18.1 Kinsey CM, Arenberg DA (2014). "Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging". Am. J. Respir. Crit. Care Med. 189 (6): 640–9. doi:10.1164/rccm.201311-2007CI. PMID 24484269.
  19. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, Choi JY, Kwon OJ, Shim YM, Kim S (2005). "Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging". Radiology. 236 (3): 1011–9. doi:10.1148/radiol.2363041310. PMID 16014441.


Template:WikiDoc Sources